Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
CeriBell | CBLL | Jan 15, 2025 | 20.03 | 0.00 |
CERo Therapeutics | CERO | Jan 15, 2025 | 2.58 | -7.86 |
Certara | CERT | Jan 15, 2025 | 11.96 | +11.36 |
Cerus | CERS | Jan 15, 2025 | 1.85 | +6.94 |
CervoMed | CRVO | Jan 15, 2025 | 2.08 | -2.35 |
CEVA | CEVA | Jan 15, 2025 | 33.77 | +4.55 |
CF Acquisition VII A | CFFS | Jan 15, 2025 | 11.28 | 0.00 |
CF Bankshares | CFBK | Jan 15, 2025 | 21.96 | +1.95 |
CF Industries | CF | Jan 15, 2025 | 96.37 | +1.45 |
CFSB Bancorp | CFSB | Jan 15, 2025 | 6.84 | +0.44 |
CG Oncology | CGON | Jan 15, 2025 | 29.61 | +5.86 |
CGI | GIB | Jan 15, 2025 | 108.38 | +0.78 |
Chain Bridge Bancorp | CBNA | Jan 15, 2025 | 24.10 | 0.00 |
Champion Homes | SKY | Jan 15, 2025 | 92.82 | +2.73 |
Champions Oncology | CSBR | Jan 15, 2025 | 9.24 | -4.45 |
ChampionX | CHX | Jan 15, 2025 | 28.87 | +2.38 |
Channel Therapeutics | CHRO | Jan 15, 2025 | 0.97 | +3.36 |
Chanson International | CHSN | Jan 15, 2025 | 5.67 | +1.25 |
ChargePoint | CHPT | Jan 15, 2025 | 1.11 | +6.73 |
Charles & Colvard | CTHR | Jan 15, 2025 | 1.53 | +2.01 |
Charles River Laboratories International | CRL | Jan 15, 2025 | 173.91 | -2.34 |
Charles Schwab | SCHW | Jan 15, 2025 | 73.66 | +1.82 |
Charlton Aria Acquisition | CHAR | Jan 15, 2025 | 9.98 | 0.00 |
Charlton Aria Acquisition Unit | CHARU | Jan 15, 2025 | 10.20 | 0.00 |
Chart Industries | GTLS-B | Jan 15, 2025 | 78.03 | +3.64 |
Chart Industries | GTLS | Jan 15, 2025 | 213.36 | +4.11 |
Charter Communications A | CHTR | Jan 15, 2025 | 348.00 | +0.49 |
Chatham Lodging Trust (REIT) A Pref | CLDT-A | Jan 15, 2025 | 20.86 | +1.76 |
Chatham Lodging Trust REIT | CLDT | Jan 15, 2025 | 8.89 | +2.30 |
Cheche Group | CCG | Jan 15, 2025 | 0.89 | +0.07 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.